Tandem Diabetes Care (TNDM) Receivables (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Receivables for 14 consecutive years, with $170.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 26.33% year-over-year to $170.0 million; the trailing twelve-month figure through Jun 2026 stood at $170.0 million (up 26.33% YoY), and the FY2025 full-year result was $173.9 million, up 42.72% from the prior year.
• Receivables grew to $170.0 million in Q2 2026 per TNDM's latest filing, from $147.6 million in the prior quarter.
• Across five years, Receivables topped out at $173.9 million in Q4 2025 and bottomed at $95.9 million in Q1 2023.
• Historically, Receivables has averaged $121.6 million across 5 years, with a median of $115.2 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Receivables dropped 9.74% in 2023, then jumped 42.72% in 2025.
• Over 5 years, Receivables stood at $119.0 million in 2022, then slipped by 7.22% to $110.5 million in 2023, then increased by 10.31% to $121.8 million in 2024, then soared by 42.72% to $173.9 million in 2025, then slipped by 2.26% to $170.0 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $170.0 million, $147.6 million, and $173.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.